Filtros de búsqueda

Lista de obras de Paola Guglielmelli

A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: morphological and molecular characteristics of a highly aggressive disease

scientific article published on 03 April 2020

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.

artículo científico publicado en 2017

A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells.

artículo científico publicado en 2016

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

artículo científico publicado en 2009

A life-threatening ruxolitinib discontinuation syndrome

artículo científico publicado en 2017

A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis

artículo científico publicado en 2020

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

artículo científico publicado en 2014

A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms

artículo científico publicado en 2010

A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis.

artículo científico publicado en 2006

A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction.

artículo científico publicado en 2008

Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis

artículo científico publicado en 2005

Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms

artículo científico publicado en 2013

Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.

artículo científico publicado en 2007

Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.

artículo científico publicado en 2016

B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis.

artículo científico publicado en 2007

BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques

artículo científico publicado en 2012

Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms.

artículo científico publicado en 2018

CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients

artículo científico publicado en 2014

CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.

artículo científico publicado en 2014

CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles

artículo científico publicado en 2017

CALR mutations in myeloproliferative neoplasms: hidden behind the reticulum.

artículo científico publicado en 2014

CXCR4-independent rescue of the myeloproliferative defect of the Gata1low myelofibrosis mouse model by Aplidin

artículo científico publicado en 2010

Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia.

artículo científico publicado en 2014

Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value

artículo científico publicado en 2014

Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms

scientific article published on 22 May 2014

Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia

artículo científico publicado en 2008

Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms

scientific article published on 12 November 2019

Characterization and discovery of novel miRNAs and moRNAs in JAK2V617F-mutated SET2 cells

artículo científico publicado en 2012

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis

artículo científico publicado en 2014

Clinical implications of the JAK2 V617F mutation in essential thrombocythemia.

artículo científico publicado en 2005

Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia

artículo científico publicado en 2007

Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib.

artículo científico publicado en 2017

Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study

artículo científico publicado en 2020

Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2.

artículo científico publicado en 2013

Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide.

artículo científico publicado en 2017

Differential amplification of murine bipotent megakaryocytic/erythroid progenitor and precursor cells during recovery from acute and chronic erythroid stress

artículo científico publicado en 2005

Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients.

artículo científico publicado en 2014

Does the nasogastric tube has a role in elective colo-rectal surgery?

scientific article published on 01 March 2012

Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera

artículo científico publicado en 2017

Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients.

artículo científico publicado en 2016

Drug-Related Cutaneous Adverse Events in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Literature Review

artículo científico publicado en 2020

EZH2 mutational status predicts poor survival in myelofibrosis.

artículo científico publicado en 2011

Effect of mutation order on myeloproliferative neoplasms

artículo científico publicado en 2015

Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis.

artículo científico publicado en 2013

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group

artículo científico publicado en 2016

Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives.

artículo científico publicado en 2009

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM090

artículo científico publicado en 2013

Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial

artículo científico publicado en 2015

Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature

artículo científico publicado en 2020

FLT3-mediated p38-MAPK activation participates in the control of megakaryopoiesis in primary myelofibrosis.

artículo científico publicado en 2011

Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis

artículo científico publicado en 2010

Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.

artículo científico publicado en 2011

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis.

artículo científico publicado en 2018

Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project

artículo científico publicado en 2018

Genetic Lesions Disrupting Calreticulin 3'-Untranslated Region In Jak2 Mutation-Negative Polycythemia Vera

artículo científico publicado en 2020

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms

artículo científico publicado en 2015

Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression

artículo científico publicado en 2011

Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms.

artículo científico publicado en 2016

Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosis

scientific article published on 12 January 2015

High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosis

artículo científico publicado en 2010

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

scientific article published on 07 January 2021

Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia

artículo científico publicado en 2010

Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN.

artículo científico publicado en 2012

Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis.

artículo científico publicado en 2008

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.

artículo científico publicado en 2010

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

artículo científico publicado en 2009

Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group

artículo científico publicado en 2019

Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia

artículo científico publicado en 2013

Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study

artículo científico publicado en 2014

Improving survival trends in primary myelofibrosis: an international study.

artículo científico publicado en 2012

Inconsistencies in the association between the JAK2V617F mutation and PRV-1 over-expression among the chronic myeloproliferative diseases

artículo científico publicado en 2006

Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.

artículo científico

Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3.

artículo científico publicado en 2010

Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia

artículo científico publicado en 2008

Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis

artículo científico publicado en 2013

Insights into JAK2-V617F mutation in CML

Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in primary myelofibrosis.

artículo científico publicado en 2015

Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients

artículo científico publicado en 2017

Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative

artículo científico publicado en 2019

JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment.

artículo científico publicado en 2011

JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.

artículo científico publicado en 2007

JAK2 mutation-related disease and thrombosis

artículo científico publicado en 2013

JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera.

scientific article published on 24 June 2009

JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib.

artículo científico publicado en 2015

JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone

artículo científico publicado en 2012

JAK2V617F mutation screening in patients with retinal vein thrombosis or recurrent fetal loss

artículo científico publicado en 2008

JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis.

artículo científico publicado en 2008

Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia

artículo científico publicado en 2008

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

artículo científico publicado en 2014

Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis

scientific article published on 11 July 2016

Mesenchymal stem cells from JAK2V617F mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele

artículo científico publicado en 2007

MicroRNA expression profile in granulocytes from primary myelofibrosis patients.

artículo científico publicado en 2007

Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms

artículo científico publicado en 2010

Molecular pathophysiology of Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mutations

scientific article published on 01 July 2008

Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1).

artículo científico publicado en 2006

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea

artículo científico publicado en 2018

Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera

scientific article published on 16 January 2020

Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms

artículo científico publicado en 2013

Mutations and prognosis in primary myelofibrosis

artículo científico publicado en 2013

Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosis

artículo científico publicado en 2019

Myelofibrosis Treatment Algorithm 2018

scholarly article by Ayalew Tefferi et al published 31 July 2018 in Blood Cancer Journal

No role for CXCL12–G801A polymorphism in the development of extramedullary disease in acute myeloid leukemia

scientific article published on 06 September 2007

Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning

artículo científico publicado en 2020

Overexpression of microRNA-16-2 contributes to the abnormal erythropoiesis in polycythemia vera

artículo científico publicado en 2011

PRV-1, erythroid colonies and platelet Mpl are unrelated to thrombosis in essential thrombocythaemia

artículo científico publicado en 2004

Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition

artículo científico publicado en 2010

Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance

artículo científico publicado en 2007

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.

artículo científico publicado en 2017

Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients

artículo científico publicado en 2011

Profound parental bias associated with chromosome 14 acquired uniparental disomy indicates targeting of an imprinted locus

artículo científico publicado en 2015

Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.

artículo científico publicado en 2016

Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden

artículo científico publicado en 2007

Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.

artículo científico publicado en 2013

Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms

artículo científico publicado en 2010

Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders-A consensus project of the Italian Society of Hematology

artículo científico publicado en 2017

Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments

scientific article published on 11 February 2008

Risk of second cancers in chronic myeloproliferative neoplasms

artículo científico publicado en 2012

Role of TGF-β1/miR-382-5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis

artículo científico publicado en 2018

Role of extracorporeal photochemotherapy in patients with refractory chronic graft-versus-host disease.

artículo científico publicado en 2005

Role of miR-34a-5p in Hematopoietic Progenitor Cells Proliferation and Fate Decision: Novel Insights into the Pathogenesis of Primary Myelofibrosis

artículo científico publicado en 2017

Ruxolitinib is an effective treatment forCALR-positive patients with myelofibrosis

scientific article published on 25 August 2015

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.

artículo científico publicado en 2017

Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia.

artículo científico publicado en 2015

STAT1 activation in association with JAK2 exon 12 mutations

artículo científico publicado en 2015

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.

artículo científico publicado en 2011

Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms.

artículo científico publicado en 2016

Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study

scientific article published on 29 May 2019

Second cancers in MPN: Survival analysis from an international study

artículo científico publicado en 2019

Significance of CTLA-4 and CD14 genetic polymorphisms in clinical outcome after allogeneic stem cell transplantation

artículo científico publicado en 2007

Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells

artículo científico publicado en 2015

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2

artículo científico publicado en 2013

Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation

scientific article published on 10 May 2019

Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases

artículo científico publicado en 2019

Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients.

artículo científico publicado en 2016

Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation.

artículo científico publicado en 2012

Struggling with myelofibrosis-associated anemia

artículo científico publicado en 2013

Systemic mastocytosis associated with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Report of three cases

artículo científico publicado en 2019

Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms

artículo científico publicado en 2013

The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion

artículo científico publicado en 2018

The ERCC2 Gln/Gln polymorphism at codon 751 is not associated with leukaemic transformation in primary myelofibrosis

artículo científico publicado en 2013

The HScore for secondary hemophagocytic lymphohistiocytosis, calculated without a marrow biopsy, is consistently low in patients with COVID-19

artículo científico publicado en 2020

The JAK2 46/1 (GGCC) MPN-predisposing haplotype: A risky haplotype, after all

scientific article published on 18 December 2018

The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera

artículo científico publicado en 2009

The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia

artículo científico publicado en 2007

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients

scientific article published on 19 February 2014

The prognostic impact of bone marrow fibrosis in primary myelofibrosis

scientific article published on 29 July 2016

The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients

artículo científico publicado en 2006

Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia.

artículo científico publicado en 2008

Thrombosis in primary myelofibrosis: incidence and risk factors

artículo científico publicado en 2009

Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis

artículo científico publicado en 2016

Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice

scientific article published on 12 December 2019

Traffic lights for ruxolitinib.

artículo científico publicado en 2017

Treatment options for essential thrombocythemia and polycythemia vera

scientific article published on February 2009

Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients

artículo científico publicado en 2014

Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium

artículo científico publicado en 2012

Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis

artículo científico publicado en 2020

Validation of the Mayo alliance prognostic system for mastocytosis

artículo científico publicado en 2019

Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis.

artículo científico publicado en 2015

What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?

artículo científico

mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms

artículo científico publicado en 2013

miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6.

artículo científico publicado en 2017

miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis

artículo científico publicado en 2014

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda